Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 146 of 6351
-
Can a new injection slow a rare heart disease?
Disease control CompletedTo evaluate the efficacy of eplontersen compared to placebo in participants with ATTR-CM receiving available standard of care (SoC).
Phase 3 • Sponsor: Ionis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Engineered immune cells take on childhood leukemia in new trial
Disease control Recruiting nowThis is an open-label, four-cohort, phase 2 study to determine the efficacy of CART19 in pediatric and young adult patientswith hypodiploid (Cohort A) or t(17;19) B-ALL (Cohort B), infants with very high risk KMT2A B-ALL (Cohort C), and in patients with central nervous system (CN…
Phase 2 • Sponsor: Stephan Grupp MD PhD • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
A Once-a-Week shot could transform hemophilia Care—Even for those with inhibitors
Disease control CompletedTreatment with PF-06741086 is anticipated to demonstrate a clinically relevant advantage and/or a major contribution to patient care in comparison to current methods of treatment for hemophilia A or B because it works differently than factor replacement products and will work in …
Phase 3 • Sponsor: Pfizer • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Immunotherapy boost may improve outcomes in returning throat cancer
Disease control Recruiting nowThis is a multicenter, randomized controlled, phase III clinical trial. The purpose of this study is to evaluate the efficacy and adverse effect of PD-1 antibody with chemoradiotherapy versus chemoradiotherapy alone in recurrent nasopharyngeal carcinoma patients.
Phase 3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Could removing tubes first, ovaries later prevent ovarian cancer just as well?
Prevention Recruiting nowThe aim of the project is to evaluate the risk-reducing salpingectomy with delayed oophorectomy as an alternative for risk-reducing salpingo-oophorectomy in high risk women with respect to ovarian cancer incidence.
Sponsor: University Medical Center Nijmegen • Aim: Prevention
Last updated Jun 27, 2026 12:04 UTC
-
Immunotherapy combo aims to extend lives in esophageal cancer
Disease control CompletedThe purpose of this study is to assess the efficacy and safety of treatment with definitive chemoradiotherapy (dCRT) + pembrolizumab (MK-3475) compared to treatment with dCRT + placebo with respect to Event-free Survival (EFS) and Overall Survival (OS) in: * participants whose t…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New hope for advanced kidney cancer: belzutifan takes on everolimus in major trial
Disease control OngoingThe primary objective of this study is to compare belzutifan to everolimus with respect to progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by Blinded Independent Central Review (BICR) and to compare everolimus …
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Virtual biopsy: a painless MRI scan that spots aggressive prostate cancer
Diagnosis Recruiting nowDiffusion Basis Spectrum Imaging (DBSI) represents a potential leap forward in improving prostate cancer early detection: a non-invasive and accurate imaging test for clinically significant prostate cancer.
Sponsor: Washington University School of Medicine • Aim: Diagnosis
Last updated Jul 16, 2026 00:00 UTC
-
Blood swap breakthrough: can exchange transfusions save sickle cell patients?
Disease control OngoingThe SCD-CARRE trial is a Phase 3, prospective, randomized, multicenter, controlled, parallel two-arm study aimed to determine if automated exchange blood transfusion and standard of care administered to high mortality risk adult SCD patients reduces the total number of episodes o…
Phase 3 • Sponsor: University of Pittsburgh • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
Double attack on blood cancer: stem cell transplant plus CAR-T shows promise
Disease control CompletedThe goal of this clinical trial is to learn if sequential CD19/CD22 CAR-T cell therapy following autologous stem cell transplantation (ASCT) works to treat relapsed or refractory large B-cell lymphoma (LBCL) in adults. It will also learn about the safety of this treatment combina…
Phase 2 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Engineered immune cells take aim at multiple Hard-to-Treat cancers
Disease control CancelledThis is a single arm study to evaluate the efficacy and safety of CEA-targeted CAR-T cells therapy for patients with relapsed/refractory CEA+ Cancer,and obtain the recommended dose and infusion plan.
Phase 1/2 • Sponsor: Chongqing Precision Biotech Co., Ltd • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Can three targeted drugs tame an aggressive blood cancer?
Disease control Recruiting nowThe aim of the CLL-RT1 trial is to evaluate the efficacy and safety of zanubrutinib (BGB-3111), a BTK inhibitor plus tislelizumab (BGB-A317), a PD1 inhibitor for treatment of patients with Richter Transformation
Phase 2 • Sponsor: German CLL Study Group • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
New targeted therapy shows promise for rare lung cancer subtype
Disease control OngoingThe reason for this study is to see if the study drug selpercatinib compared to a standard treatment is effective and safe in participants with rearranged during transfection (RET) fusion-positive non-squamous non-small cell lung cancer (NSCLC) that has spread to other parts of t…
Phase 3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New lung cancer pill shows promise in Head-to-Head trial
Disease control CompletedThis Phase III study will be conducted to evaluate the efficacy and safety of YH25448 as first-line treatment in locally advanced or metastatic Non-small Cell Lung Cancer (NSCLC) patients with EGFR mutations
Phase 3 • Sponsor: Yuhan Corporation • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Can hepatitis c be cured in just 4 weeks? a new trial puts it to the test
Cure Recruiting nowThis study aims to evaluate the efficacy, safety and feasibility of four weeks of sofosbuvir plus glecaprevir-pibrentasvir, followed by immediate retreatment of virological relapse with glecepravir-pibrentasvir for 12 weeks, in treatment-naïve participants with chronic HCV infect…
Phase 4 • Sponsor: Kirby Institute • Aim: Cure
Last updated Jul 31, 2026 00:00 UTC
-
New hope for Hard-to-Treat lymphoma: targeted drug combo shows promise in phase 3 trial
Disease control CompletedThis study is a multicenter, open-label study of polatuzumab vedotin administered by intravenous (IV) infusion in combination with rituximab, gemcitabine and oxaliplatin (R-GemOx) in participants with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The study compris…
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Stem cell heart patch could be lifeline for failing hearts
Disease control Recruiting nowThe BioVAT-HF trial will test the hypothesis that cardiomyocyte implantation via engineered heart muscle (EHM), the proposed investigational medicinal product (IMP; designated "Biological Ventricular Assist Tissue" or BioVAT), results in sustainable remuscularization and biologic…
Phase 1/2 • Sponsor: University Medical Center Goettingen • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Could a stem cell infusion free kidney transplant patients from lifelong drugs?
Disease control Recruiting nowThis study will determine whether a preparatory regimen including total lymphoid irradiation (TLI), total body irradiation (TBI), anti-thymocyte globulin (ATG) and infusion of the donor hematopoietic stem cells when given along with recipient regulatory T cells (Tregs) will allow…
Phase 1 • Sponsor: Stanford University • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New targeted combo shows promise in slowing advanced breast cancer
Disease control OngoingThis study will evaluate the efficacy, safety, and pharmacokinetics of inavolisib in combination with palbociclib and fulvestrant compared with placebo plus palbociclib and fulvestrant in participants with PIK3CA-mutant, hormone receptor (HR)-positive, HER2-negative locally advan…
Phase 2/3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Monthly shot could free kids with hemophilia from frequent infusions
Disease control CompletedPrimary Objective: \- To confirm appropriate dose levels of fitusiran when administered to male pediatric participants (ages 1 to \<12 years of age) with severe hemophilia A or B Secondary Objectives: * To characterize the safety and tolerability * To determine fitusiran plasm…
Phase 3 • Sponsor: Genzyme, a Sanofi Company • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC